Young Man Rides Across Europe to Raise Money for Father's Pleural Mesothelioma Fight

Young student Jamie Menzies from Potton, England is launching a bike tour that travels across Europe to raise money for a local hospital's charity in honor of his father, who was diagnosed with pleural mesothelioma in November 2010. Menzies seeks to raise money for Papworth Hospital, the United Kingdom's largest cardiothoracic hospital, where his father is currently being treated. Menzies' father's doctors have determined that his mesothelioma has developed as the result of asbestos exposure. Various medical studies have linked asbestos exposure as the cause of mesothelioma in upwards of 90 percent of cases. Malignant mesothelioma develops in the lining of the vital organs of the body such as the lungs and abdomen. In return for the outstanding care that Jamie's father is receiving, 22-year-old Menzies will cycle 100 meters for every patient that Papworth Hospital treats in an average year. The hospital treats approximately 22,400 patients annually, which equates to a total length of 2,240km (1,391.8 miles). Menzies has planned the bike tour to start at the Papworth Hospital in England on June 8, 2011 and extend to Geneva, Switzerland and back within 23 days. The money raised through donations will be given to the hospital's Mesothelioma Trust Fund to be used for mesothelioma research. Jamie, who enjoys outdoor adventures teetering on the edge of extreme, said, "I would not even remotely consider myself much of a cyclist. The last bike I had was when I was about 10. To b...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news

Related Links:

Malignant pleural mesothelioma is a rare aggressive cancer, with insidious growth, and is associated with poor outcomes that have not improved over the years. A task force made up of members of the European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) societies, who are experts in the field of malignant mesothelioma, reviewed the literature from 2009 to 2018 to update the 2009 guidelines concerning epidemiology, diagnosis, staging, and treatment, including surgical, radiotherapy, and med...
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Special Article Source Type: research
The continued underutilization of aggressive surgery for peritoneal mesothelioma is shortening survival time dramatically for patients who could qualify for, and benefit from, the highly effective procedure. Only a third of those diagnosed with peritoneal mesothelioma are undergoing potentially curative cytoreductive mesothelioma surgery, according to a comprehensive study of the National Cancer Database by researchers at Inova Fairfax Medical Center in Virginia. Annals of Surgical Oncology published the mesothelioma study earlier this year. “Patients who have the surgery perform much better than those who do not. Ye...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer. The long latency from asbestos exposure to MPM development, as well as the absence of early symptoms, lead to late diagnosis and very poor prognosis, with a life expectancy of 9-18 months from diagnosis [1]. Only a small number of patients is suitable for multimodal therapy, including surgery, and the majority of patients receive palliative chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis. The aim of this study was to identify genetic mutations associated with poor or extended survival in patients who received palliative chemotherapy.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Researchers in Spain have discovered a drug combination showing potential in treating the most difficult-to-treat type of malignant mesothelioma. Selumetinib and AZD8186, already being studied separately in clinical trials for other cancers, displayed efficacy when used in combination on mesothelioma of the sarcomatoid cell type. Researchers at the Spanish National Cancer Research Centre made the discovery during their study using mice models and human tumor cells in the laboratory. “The findings, we hope, are relevant,” Dr. Paco Real, who led the study, told The Mesothelioma Center at Asbestos.com. “We d...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at Asbestos.com. “But we’ve shown a meaningful survival.” Kluger,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer, with a five-year survival rate of
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and mediastinal malignancies Source Type: research
The Baylor College of Medicine in Houston has opened its latest clinical trial for mesothelioma patients to study the effectiveness of a novel immunotherapy combination. The nonsurgical, single-center study is looking for a dozen patients whose pleural mesothelioma has progressed after at least one regimen of chemotherapy. The phase II clinical trial involves Opdivo (nivolumab) and MTG201, a modified adenovirus designed to increase the efficacy of certain types of immunotherapy drugs. The combination was especially effective in preclinical mouse models. “We’re excited about the prospects of this combination,&rd...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Environmental Health | Funding | Heart | Hospitals | Men | Mesothelioma | Palliative | Palliative Care | Students | Study | Universities & Medical Training